Rasburicase: Potential role in managing tumor lysis in patients with hematological malignancies

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 429-433

  Goldman, Stanton C ^a  

^a TEXAS ONCOLOGY   (United States)

Author keywords

Acute tumor lysis; Allopurinol; Hematological malignany; Rasburicase; Uric acid

Indexed keywords

ALLANTOIN; ALLOPURINOL; BICARBONATE; BRONCHODILATING AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; OXIDOREDUCTASE; RASBURICASE; STEROID; URIC ACID;

ADULT; ALKALINIZATION; B CELL LYMPHOMA; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HIGH RISK POPULATION; HUMAN; HYDRATION; HYPERSENSITIVITY REACTION; HYPERURICEMIA; KIDNEY FAILURE; LEUKEMIA; METHEMOGLOBINEMIA; PHASE 3 CLINICAL TRIAL; PRURITUS; REVIEW; TUMOR CELL DESTRUCTION; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; WHEEZING;

EID: 0042510826     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.429     Document Type: Review

References (15)

1. Andreoli SP, Clark JH, McGuire WA, Bergstein M. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J. Pediatr. 109(2), 292-298 (1986).
2. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: iv. use for prevention and treatment of hyperuricemia. J. Clin. Oncol. 18(8), 1758-1763 (2000).
3. Pui CH, Relling MV, Lascombes F et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11, 1813-1816 (1997).
4. Bowman WP, Shuster JJ, Cook B et al. Improved survival for children with B-cell acute lymphoblastic leukemia and Stage IV small noncleaved cell lymphoma: a pediatric oncology group study. J. Clin. Oncol. 14, 1252-1261 (1996).
5. Atra A, Gerrard M, Hobson R, Imeson JD, Ashley S, Pinkerton CR. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and Stage IV B-cell non-Hodgkin's lymphoma (B-NHL): results of the UKCCSG 9003 protocol. Br. J. Cancer 77, 2281-2285 (1998).
6. Stapleton FB, Strother DR, Roy S III, Wyatt RJ, McKay CP, Murphy SB. Acute renal failure at onset of therapy for advanced stage Burkitt's lymphoma and B-cell acute lymphoblastic lymphoma. Pediatrics 82, 863-869 (1998).
7. Patte C, Auperi n A, Michon J et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97, 3370-3379 (2001).
8. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol. 19(3), 697-704 (2001).
9. Goldman SC, Hoicenberg JS, Finklestein JZ et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97(10), 2998 (2001).
10. Jeha S, McDonald L, Irwin D et al. Recombinant urate oxidase (Elitek™) is safe and effective in prevention and treatment of malignancy-associated hyperuricemia in adult patients. Blood 100(11), 556a (2002) (Abstract).
11. Coiffier B, Mounier N, Bologna S et al. Final results of the efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia in patients with aggressive lymphoma (GRAAL 1 study). Blood 100(11), 359a (2002).
12. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15, 1505-1509 (2001).
13. Pui CH, Jeha S, Irwin D et al. Recombinant urate oxidase (rasburicase, Elitek) for prevention and treatment of malignancy-associated hyperuricemia: updated results of a compassionate use trial. Blood 100(11), 556a (2002).
14. Lascombes F, Sommelet D, Gebhard F et al. High efficacy of recombinant urate oyidase in prevention of renal failure related to tumor lysis syndrome (TLS). Blood 92(10), 237b (1998).
15. Annemans L, Moeremans K, Lamotte M et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support. Care Cancer 11, 249-257 (2003).